Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Sponsor
Chinese Pulmonary Vascular Disease Research Group (Other)
Overall Status
Recruiting
CT.gov ID
NCT05388682
Collaborator
(none)
200
1
347.4
0.6
Study Details
Study Description
Brief Summary
evaluate the effect of medical treatment and percutaneous transluminal pulmonary angioplasty on takayasu arteritis with pulmonary artery involvement
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Observation of Long Term Effect of Medical and PTPA Treatment on Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Actual Study Start Date
:
Jan 19, 2014
Anticipated Primary Completion Date
:
Dec 31, 2042
Anticipated Study Completion Date
:
Dec 31, 2042
Outcome Measures
Primary Outcome Measures
- all cause death [2014/1/1-2042/12/31]
all cause death
- mean pulmonary arterial pressure change [2014/1/1-2042/12/31]
change of mean pulmonary arterial pressure after treatment
- pulmonary vascular resistance change [2014/1/1-2042/12/31]
chagne of pulmonary vascular resistance after treatment
- 6MWD change [2014/1/1-2042/12/31]
change of six minute walk distance after treatment
- peak VO2 change [2014/1/1-2042/12/31]
change of peak oxygen consumption after treatment
- NT-proBNP change [2014/1/1-2042/12/31]
change of NT-proBNP after treatment
- RV/LV change [2014/1/1-2042/12/31]
change of right ventricular end-diastolic diameter versus laboratory left ventricular end-diastolic diameterafter treatment
- CI change [2014/1/1-2042/12/31]
change of cardiac index after treatment
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- patients diagnosed with Takayasu arteries with pulmonary arteries involvement
Exclusion Criteria:
- Patients had pulmonary artery stenosis arising from CTEPH, fibrosing mediastinitis and congenital pulmonary artery stenosis
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | uwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing | China | 100000 |
Sponsors and Collaborators
- Chinese Pulmonary Vascular Disease Research Group
Investigators
- Principal Investigator: zhihong Liu, doctor, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Chinese Pulmonary Vascular Disease Research Group
ClinicalTrials.gov Identifier:
NCT05388682
Other Study ID Numbers:
- TAPAI
First Posted:
May 24, 2022
Last Update Posted:
May 24, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chinese Pulmonary Vascular Disease Research Group
Additional relevant MeSH terms: